Ending the HIV epidemic: Where does Europe stand?

November 29, 2018

From diagnosis of HIV to successful viral suppression: in a rapid communication published in Eurosurveillance today, ECDC and co-authors from Public Health England and The National AIDS Trust summarise the progress towards HIV elimination in 52 countries in Europe and Central Asia. The main issues: diagnosing those who are unaware of their HIV infection and treating them.

The global targets set out by UNAIDS for 2020 are to diagnose 90% of all HIV-positive people, provide antiretroviral therapy for 90% of those diagnosed, and achieve viral suppression for 90% of those treated (known as 90-90-90 targets). In 2018, 52 of 55 countries completed the survey indicating the progress towards these targets in Europe and Central Asia.

Between "substantial progress" and "concerning"

Is Europe on track to end AIDS by 2020? Following analysis of the data provided by the 52 countries in 2018, the progress towards the 90-90-90 targets stands at 86%-91%-92% in the EU/EEA. This means that overall, countries in the EU/EEA are on track to reach the targets by 2020. Looking at the whole Region, however, a striking drop in the second stage of the continuum is apparent: across Europe and Central Asia, the figures show a significant gap in the amount of people who are diagnosed with HIV but not receiving treatment: 80%-64%-86%. The article provides results on the targets for each of the reporting countries.

The authors acknowledge "substantial progress" towards the 90-90-90 targets across Europe and Central Asia. However, among the estimated 2.1 million people living with HIV in Europe and Central Asia "only two out of five are estimated to be virally suppressed in 2018". Furthermore, "the substantial drop-off between the percentages diagnosed and treated in the East sub-region is concerning since it enables preventable deaths, serious illness and onward transmission."

The results give new insights into necessary steps in the regional or national HIV responses. As almost two-thirds of the 1.2 million people across the region with transmissible virus are diagnosed but only half of those are on treatment, "the biggest public health impact could be achieved through rapid and sustained scale up of treatment", according to the authors. This is particularly true for countries in the east of the region where the outcome was 76%-46%-78%.

Policies that diversify and enhance the offer of HIV tests could help address the problem of late diagnosis across Europe, as outlined in the new ECDC guidance on HIV, hepatitis B and C testing. This would include testing for indicator conditions, during screenings for other sexually transmitted infections, in community-based settings, as self/home-testing and for partner notification.

The authors highlight that the 90-90-90 targets remain a "powerful tool to assess progress towards HIV elimination and drive standards in care" for people living with HIV. But these targets do not provide a comprehensive picture of the public health response to HIV. "Each 'last 10 percent' includes people especially marginalised from healthcare services."

What are the 90-90-90 targets?

The so-called continuum of HIV care is a framework which allows countries to monitor the effectiveness of key areas in the response to the HIV epidemic along several stages, from diagnosis towards viral suppression. The overall aim is to that people living with HIV are diagnosed (early) and receive antiretroviral treatment (ART) which leads to viral suppression, i.e. the virus is no longer detectable in the blood. Such an undetectable viral load also means that HIV positive people on effective treatment do not transmit the virus.

Based on the findings of the ECDC Dublin Declaration report on the continuum in 2015, ECDC now monitors a four-stage continuum that is directly relevant in the European region. Stage 1 looks at the estimated number of all people living with HIV (PLHIV); stage 2 at the number of all PLHIV who have been diagnosed; stage 3 at the number on PLHIV who have been diagnosed and who are on ART; and stage 4 comprises the number of PLHIV on ART who are virally suppressed. In 2018, 34 of 55 countries provided data on all four continuum stages.
-end-
Read more

ECDC Guidance on HIV, hepatitis B and C testing http://bit.ly/TestGui

Progress reports and evidence briefs: Monitoring the implementation of the Dublin Declaration Dublin http://bit.ly/DublinDeclaration

HIV/AIDS surveillance in Europe 2018 - 2017 data https://ecdc.europa.eu/sites/portal/files/documents/hiv-aids-surveillance-in-europe-2018.pdf

European Centre for Disease Prevention and Control (ECDC)

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.